Financial Results & Reports
ViroGates’ current and previous financial results, reports, analyst presentations, IPO documents, and more, are listed below.
Financial Results, H1 2022
Annual Report 2021
2021 was an exciting year for ViroGates. The company delivered revenue growth of 43% and achieved extraordinary scientific results. However, the global COVID-19 continued to affect the business negatively with many hospitals unable to onboard new technologies during a state of emergency. Despite the challenges, ViroGates welcomed several new customers across markets and managed to shift sales further towards clinically relevant products.
Previous Interim/Half-Year Reports
Analyst Reports
2022
10 May 2022:Market Focus Update by Västra Hamnen Corporate Finance
25 March 2022:Market Focus Update by Västra Hamnen Corporate Finance
2021
18 November 2021:Market Focus Update by Västra Hamnen Corporate Finance
2020
6 November 2020:Analyse af ViroGates A/S by Aktieinfo
27 October 2020:Market Focus Update by Västra Hamnen Corporate Finance
14 August 2020:Market Focus Update by Västra Hamnen Corporate Finance
30 March 2020: Market Focus Update by Västra Hamnen Corporate Finance
29 January 2020: Market Focus Initial Research by Västra Hamnen Corporate Finance
2019
12 April 2019:Analyse af ViroGates A/S by Aktieinfo
2018
4 October 2018:Analyse af ViroGates A/S by Aktieinfo
IPO 2018 Documents
ViroGates Prospectus 2018 (Full version in English)
ViroGates Prospectus 2018 (Summary in Swedish)
ViroGates Prospectus 2018 Announcement
ViroGates Brochure (in Swedish)
11 June 2018: Presentation at Aktiespararnas Småbolagsdag in Stockholm
12 June 2018: Presentation at InvestorDagen by the Danish Shareholders’ Association in Aarhus
